Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes

Daiichi Sankyo logo

Daiichi Sankyo

Status and phase

Completed
Phase 3

Conditions

Type 2 Diabetes

Treatments

Drug: Colesevelam hydrochloride

Study type

Interventional

Funder types

Industry

Identifiers

NCT00151762
WEL-304

Details and patient eligibility

About

This extension study is designed to evaluate the long-term safety and tolerability of colesevelam hydrochloride (WelChol®) in patients with type 2 diabetes.

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion/Rollover Criteria:

  • Patients who have completed studies WEL-301, WEL-302, or WEL-303 with treatment compliance at least 80%
  • Patients who have completed studies WEL-301, WEL-302, or WEL-303 who have not met withdrawal criteria

Trial contacts and locations

64

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems